Which has stronger valuation and earnings, XENE or SLDB?

Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xenon Pharmaceuticals N/A N/A -$345.91M -$4.74 N/A Solid Biosciences N/A N/A -$174.32M -$1.91 N/A

Is XENE or SLDB more profitable?

Xenon Pharmaceuticals' return on equity of -43.98% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Xenon Pharmaceuticals N/A -43.98% -41.72% Solid Biosciences N/A -71.35% -60.58%

Does the media refer more to XENE or SLDB?

In the previous week, Xenon Pharmaceuticals had 16 more articles in the media than Solid Biosciences. MarketBeat recorded 18 mentions for Xenon Pharmaceuticals and 2 mentions for Solid Biosciences. Xenon Pharmaceuticals' average media sentiment score of 1.20 beat Solid Biosciences' score of 0.54 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 8 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solid Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SLDB or AMLX more profitable?

Amylyx Pharmaceuticals' return on equity of -52.92% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Solid Biosciences N/A -71.35% -60.58% Amylyx Pharmaceuticals N/A -52.92% -48.53%

Does the media favor SLDB or AMLX?

In the previous week, Amylyx Pharmaceuticals had 3 more articles in the media than Solid Biosciences. MarketBeat recorded 5 mentions for Amylyx Pharmaceuticals and 2 mentions for Solid Biosciences. Amylyx Pharmaceuticals' average media sentiment score of 0.99 beat Solid Biosciences' score of 0.54 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SLDB or LEGN?

In the previous week, Legend Biotech had 5 more articles in the media than Solid Biosciences. MarketBeat recorded 7 mentions for Legend Biotech and 2 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.54 beat Legend Biotech's score of 0.33 indicating that Solid Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, SLDB or ELVN?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solid Biosciences N/A N/A -$174.32M -$1.91 N/A Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A

Is SLDB or ELVN more profitable?

Enliven Therapeutics' return on equity of -18.55% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Solid Biosciences N/A -71.35% -60.58% Enliven Therapeutics N/A -18.55% -18.09%

Does the media prefer SLDB or ELVN?

In the previous week, Enliven Therapeutics had 2 more articles in the media than Solid Biosciences. MarketBeat recorded 4 mentions for Enliven Therapeutics and 2 mentions for Solid Biosciences. Enliven Therapeutics' average media sentiment score of 1.12 beat Solid Biosciences' score of 0.54 indicating that Enliven Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enliven Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SLDB or IDYA?

In the previous week, Solid Biosciences and Solid Biosciences both had 2 articles in the media. Solid Biosciences' average media sentiment score of 0.54 beat IDEAYA Biosciences' score of 0.42 indicating that Solid Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEAYA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Solid Biosciences (SLDB) Competitors

$6.85 -0.13 (-1.86%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$6.86 +0.01 (+0.07%)

As of 10/2/2026 07:47 PM Eastern

Compare

SLDB vs. XENE, AMLX, LEGN, ELVN, and IDYA

Should you buy Solid Biosciences stock or one of its competitors? Solid Biosciences's main competitors and comparable companies include Xenon Pharmaceuticals (XENE), Amylyx Pharmaceuticals (AMLX), Legend Biotech (LEGN), Enliven Therapeutics (ELVN), and IDEAYA Biosciences (IDYA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Solid Biosciences compare to Xenon Pharmaceuticals?

Xenon Pharmaceuticals (NASDAQ:XENE) and Solid Biosciences (NASDAQ:SLDB) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Xenon Pharmaceuticals' return on equity of -43.98% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%
Solid Biosciences	N/A	-71.35%	-60.58%

Xenon Pharmaceuticals currently has a consensus target price of $70.27, suggesting a potential upside of 84.82%. Solid Biosciences has a consensus target price of $18.69, suggesting a potential upside of 172.88%. Given Solid Biosciences' higher probable upside, analysts clearly believe Solid Biosciences is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

95.4% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 2.9% of Xenon Pharmaceuticals shares are owned by insiders. Comparatively, 2.7% of Solid Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Xenon Pharmaceuticals had 16 more articles in the media than Solid Biosciences. MarketBeat recorded 18 mentions for Xenon Pharmaceuticals and 2 mentions for Solid Biosciences. Xenon Pharmaceuticals' average media sentiment score of 1.20 beat Solid Biosciences' score of 0.54 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	8 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solid Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xenon Pharmaceuticals has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.47, suggesting that its stock price is 147% more volatile than the broader market.

Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	N/A	N/A	-$345.91M	-$4.74	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A

Summary

Xenon Pharmaceuticals beats Solid Biosciences on 9 of the 14 factors compared between the two stocks.

How does Solid Biosciences compare to Amylyx Pharmaceuticals?

Solid Biosciences (NASDAQ:SLDB) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

Amylyx Pharmaceuticals has higher revenue and earnings than Solid Biosciences. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
Amylyx Pharmaceuticals	$87.37M	35.44	-$144.74M	-$1.43	N/A

Amylyx Pharmaceuticals' return on equity of -52.92% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by company insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Solid Biosciences has a beta of 2.47, meaning that its share price is 147% more volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.1, meaning that its share price is 110% less volatile than the broader market.

In the previous week, Amylyx Pharmaceuticals had 3 more articles in the media than Solid Biosciences. MarketBeat recorded 5 mentions for Amylyx Pharmaceuticals and 2 mentions for Solid Biosciences. Amylyx Pharmaceuticals' average media sentiment score of 0.99 beat Solid Biosciences' score of 0.54 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solid Biosciences currently has a consensus price target of $18.69, suggesting a potential upside of 172.88%. Amylyx Pharmaceuticals has a consensus price target of $38.86, suggesting a potential upside of 39.82%. Given Solid Biosciences' higher probable upside, analysts clearly believe Solid Biosciences is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Amylyx Pharmaceuticals beats Solid Biosciences on 11 of the 15 factors compared between the two stocks.

How does Solid Biosciences compare to Legend Biotech?

Solid Biosciences (NASDAQ:SLDB) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Solid Biosciences has a net margin of 0.00% compared to Legend Biotech's net margin of -7.21%. Legend Biotech's return on equity of -8.71% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
Legend Biotech	-7.21%	-8.71%	-5.40%

Solid Biosciences has a beta of 2.47, indicating that its stock price is 147% more volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 2.7% of Solid Biosciences shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Solid Biosciences has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
Legend Biotech	$1.03B	3.50	-$296.80M	-$0.25	N/A

In the previous week, Legend Biotech had 5 more articles in the media than Solid Biosciences. MarketBeat recorded 7 mentions for Legend Biotech and 2 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.54 beat Legend Biotech's score of 0.33 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Solid Biosciences currently has a consensus target price of $18.69, suggesting a potential upside of 172.88%. Legend Biotech has a consensus target price of $55.79, suggesting a potential upside of 200.41%. Given Legend Biotech's higher possible upside, analysts clearly believe Legend Biotech is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Legend Biotech	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.53

Summary

Solid Biosciences beats Legend Biotech on 9 of the 15 factors compared between the two stocks.

How does Solid Biosciences compare to Enliven Therapeutics?

Solid Biosciences (NASDAQ:SLDB) and Enliven Therapeutics (NASDAQ:ELVN) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

Solid Biosciences currently has a consensus price target of $18.69, suggesting a potential upside of 172.88%. Enliven Therapeutics has a consensus price target of $74.44, suggesting a potential upside of 58.49%. Given Solid Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Solid Biosciences is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 2.7% of Solid Biosciences shares are owned by insiders. Comparatively, 3.0% of Enliven Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Enliven Therapeutics' return on equity of -18.55% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
Enliven Therapeutics	N/A	-18.55%	-18.09%

Solid Biosciences has a beta of 2.47, indicating that its share price is 147% more volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

In the previous week, Enliven Therapeutics had 2 more articles in the media than Solid Biosciences. MarketBeat recorded 4 mentions for Enliven Therapeutics and 2 mentions for Solid Biosciences. Enliven Therapeutics' average media sentiment score of 1.12 beat Solid Biosciences' score of 0.54 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enliven Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Enliven Therapeutics beats Solid Biosciences on 8 of the 13 factors compared between the two stocks.

How does Solid Biosciences compare to IDEAYA Biosciences?

Solid Biosciences (NASDAQ:SLDB) and IDEAYA Biosciences (NASDAQ:IDYA) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

IDEAYA Biosciences has higher revenue and earnings than Solid Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
IDEAYA Biosciences	$234.13M	14.02	-$113.70M	-$1.94	N/A

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Solid Biosciences has a beta of 2.47, meaning that its share price is 147% more volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market.

Solid Biosciences has a net margin of 0.00% compared to IDEAYA Biosciences' net margin of -75.93%. IDEAYA Biosciences' return on equity of -16.73% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%

Solid Biosciences currently has a consensus price target of $18.69, indicating a potential upside of 172.88%. IDEAYA Biosciences has a consensus price target of $52.69, indicating a potential upside of 41.04%. Given Solid Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Solid Biosciences is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Solid Biosciences and Solid Biosciences both had 2 articles in the media. Solid Biosciences' average media sentiment score of 0.54 beat IDEAYA Biosciences' score of 0.42 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEAYA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Solid Biosciences and IDEAYA Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

Get Solid Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLDB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLDB vs. The Competition

Export

Metric	Solid Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$748.43M	$3.87B	$7.14B	$13.10B
Dividend Yield	N/A	3.64%	2.53%	16.77%
P/E Ratio	-3.59	12.93	273.77	26.04
Price / Sales	N/A	1,236.59	589.92	77.16
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	3.00	16.63	10.92	6.30
Net Income	-$174.32M	-$22.67M	$3.50B	$361.43M
7 Day Performance	-6.04%	-3.10%	-2.07%	-1.67%
1 Month Performance	-34.26%	-10.70%	-6.21%	-4.51%
1 Year Performance	16.10%	19.46%	7.45%	2.03%

Solid Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLDB Solid Biosciences	2.0897 of 5 stars	$6.85 -1.9%	$18.69 +172.9%	+19.3%	$748.43M	N/A	N/A	121	Positive News
XENE Xenon Pharmaceuticals	3.839 of 5 stars	$38.06 +4.1%	$70.93 +86.4%	-3.0%	$3.78B	$7.50M	N/A	370	Trending News Analyst Upgrade Insider Trade
AMLX Amylyx Pharmaceuticals	3.4163 of 5 stars	$30.14 -1.5%	$38.86 +28.9%	+109.1%	$3.68B	$87.37M	N/A	136	News Coverage
LEGN Legend Biotech	3.5557 of 5 stars	$19.06 +3.3%	$53.14 +178.8%	-42.5%	$3.61B	$1.03B	N/A	2,965	News Coverage Insider Trade
ELVN Enliven Therapeutics	2.9086 of 5 stars	$45.17 -2.0%	$75.00 +66.0%	+135.8%	$3.53B	N/A	N/A	67	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLDB) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Solid Biosciences (SLDB) Competitors

SLDB vs. XENE, AMLX, LEGN, ELVN, and IDYA

How does Solid Biosciences compare to Xenon Pharmaceuticals?

Summary

How does Solid Biosciences compare to Amylyx Pharmaceuticals?

Summary

How does Solid Biosciences compare to Legend Biotech?

Summary

How does Solid Biosciences compare to Enliven Therapeutics?

Summary

How does Solid Biosciences compare to IDEAYA Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLDB vs. The Competition

Solid Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Solid Biosciences (SLDB) Competitors

SLDB vs. XENE, AMLX, LEGN, ELVN, and IDYA

How does Solid Biosciences compare to Xenon Pharmaceuticals?

Is XENE or SLDB more profitable?

Do analysts recommend XENE or SLDB?

Do institutionals & insiders hold more shares of XENE or SLDB?

Does the media refer more to XENE or SLDB?

Which has more risk and volatility, XENE or SLDB?

Which has stronger valuation and earnings, XENE or SLDB?

Summary

How does Solid Biosciences compare to Amylyx Pharmaceuticals?

Which has preferable valuation and earnings, SLDB or AMLX?

Is SLDB or AMLX more profitable?

Do institutionals and insiders hold more shares of SLDB or AMLX?

Which has more risk & volatility, SLDB or AMLX?

Does the media favor SLDB or AMLX?

Do analysts recommend SLDB or AMLX?

Summary

How does Solid Biosciences compare to Legend Biotech?

Is SLDB or LEGN more profitable?

Which has more volatility and risk, SLDB or LEGN?

Do institutionals & insiders have more ownership in SLDB or LEGN?

Which has preferable earnings and valuation, SLDB or LEGN?

Does the media favor SLDB or LEGN?

Do analysts prefer SLDB or LEGN?

Summary

How does Solid Biosciences compare to Enliven Therapeutics?

Do analysts rate SLDB or ELVN?

Which has stronger earnings and valuation, SLDB or ELVN?

Do insiders & institutionals hold more shares of SLDB or ELVN?

Is SLDB or ELVN more profitable?

Which has more volatility and risk, SLDB or ELVN?

Does the media prefer SLDB or ELVN?

Summary

How does Solid Biosciences compare to IDEAYA Biosciences?

Which has stronger valuation & earnings, SLDB or IDYA?

Do institutionals and insiders believe in SLDB or IDYA?

Which has more volatility and risk, SLDB or IDYA?

Is SLDB or IDYA more profitable?

Do analysts recommend SLDB or IDYA?

Does the media prefer SLDB or IDYA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLDB vs. The Competition

Solid Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools